Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-2018682 SCHEMBL29692360 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR5CYP2C9 | |
| Gsk-2018682 SCHEMBL402827 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR5CYP2C9 | |
| Gsk-2018682 SCHEMBL401576 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL400014 | 0.95 | S1PR1 (0.91) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL400074 | 0.91 | S1PR1 (0.83) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL2124526 | 0.91 | S1PR1 (0.83) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL401724 | 0.89 | S1PR1 (0.92) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL404160 | 0.88 | S1PR1 (0.78) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL2125416 | 0.88 | S1PR1 (0.78) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL1398446 | 0.88 | S1PR1 (0.78) | S1PR1S1PR3S1PR5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120392760-A | Application of GSK2018682 in preparation of medicine for resisting gram-positive bacterial infection | 深圳市南山区人民医院 | 2025-08-01 | — | — | CN | disclosed |
| US-20250228850-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | IDORSIA PHARMACEUTICALS LTD. (CH) | 2025-07-17 | — | — | US | disclosed |
| US-20250170119-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2025-05-29 | — | — | US | disclosed |
| US-20250032474-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2025-01-30 | — | — | US | disclosed |
| EP-4463154-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2024-11-20 | — | — | EP | disclosed |
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | AC BIOSCIENCE (CH) | 2023-12-26 | — | — | US | disclosed |
| WO-2023135207-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212156-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-19 | — | — | EP | disclosed |
| EP-4051250-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | Idorsia Pharmaceuticals Ltd (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114599363-A | Combinations of CXCR7 antagonists with S1P1 receptor modulators | 爱杜西亚药品有限公司 | 2022-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | SPHK1, S1PR1, S1PR2 | S1PR1 2/4885S1PR3 6/4885S1PR5 8/4885 |
| US-20250170119-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885S1PR5 3/4885 |
| US-20250228850-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | CXCR1, CXCR5, CXCL12 | S1PR1 5/4885S1PR3 12/4885S1PR5 10/4885 |
| US-20250032474-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885S1PR5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.